Skip to content

Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing

Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03284983
Acronym
SFD
Enrollment
30
Registered
2017-09-15
Start date
2017-07-01
Completion date
2017-10-01
Last updated
2017-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery, Suture, Complication, Suture; Complications, Infection or Inflammation, Wound, Wound Complication, Wound Dehiscence, Wound of Skin

Brief summary

The investigators wish to determine how suture spacing (5 mm vs. 10 mm) affects cosmetic outcome and development of train tracking in wounds. Linear wounds with sutures spaced closer together may not be as cosmetically appealing when compared to those that have larger spacing between sutures. Suturing closer together constricts blood flow and increases tension that ultimately results in more tissue necrosis and a less appealing outcome. The investigators also aim to conclude if 5 mm or 10 mm suture spacing results in less complications.

Interventions

OTHERSuture spacing for wound closure

The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.

Sponsors

Samaritan Health Services
CollaboratorOTHER
Silver Falls Dermatology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female patients, at least 18 years of age, undergoing surgical excision of biopsy-proven skin cancers on the trunk or extremities at Silver Falls Dermatology & Allergy outpatient clinic in Salem, Oregon. Patients with elliptical excisions with length greater than 4.0 centimeters were included.

Exclusion criteria

* Patients with prior scars within 2.5cm of the proposed elliptical excision, failure to comply with wound care instructions or failure to follow up.

Design outcomes

Primary

MeasureTime frameDescription
Change in cosmetic outcome of 5 mm versus 10 mm suture spacing on wound healing6 monthsThe wound was divided in half by placing a single 4-0 Polysorb suture in the midpoint of the wound based on ruler measurement. Simple interrupted nylon sutures were spaced approximately 5mm or 10mm apart depending on side. The sutures were then removed at 2-week follow-up appointment. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician. The observer scale consists of six items (vascularity, pigmentation, thickness, relief, pliability and surface area), and all items were scored on a scale from 1 ('like normal skin') to 10 ('worst scar imaginable'). The patient scale also includes six items (color, itch, pain, thickness, stiffness, and irregularity) and all items were scored on a similar scale from 1 ('like normal skin') to 10 ('worst scar imaginable').

Secondary

MeasureTime frameDescription
Change in wound complications of 5 mm versus 10 mm suture spacing on wound healing2 weeksWounds were also assessed for complications. Difficulty removing sutures was assessed by presence of either one of the following: unable to directly visualize suture knot or need to probe into wound to remove suture. Wound dehiscence was defined as at least a 1mm separation of the wound edge for at least 50% of the length of the wound closure. Edge necrosis was defined as eschar and necrosis of the wound edge for at least 50% of the wound closure. Infection was defined as any wound that had redness, pain and exudate.

Countries

United States

Contacts

Primary ContactWilliam Lear, MD
wlear1@gmail.com503 362 8385
Backup ContactCollin M Blattner, DO
collin.blattner@gmail.com503 362 8385

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026